New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis

Hemalatha Naidu, Priyanka Karagaiah, Anant Patil, Paul Yamauchi, Leon Kircik, Stephan Grabbe, Mohamad Goldust

Research output: Contribution to journalArticlepeer-review


Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and improving symptoms. These therapeutic agents are administered according to disease severity. The improvement is assessed by the Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA), in which the appearance and extension of the lesions are taken into account. We searched for English-language literature regarding phase 2 and phase 3 trial drugs in the treatment of psoriasis in the following databases: PubMed, Scopus, Embase, Google Scholar, The Cochrane Library, and EBSCO, The keywords used include psoriasis, biologics, plaque psoriasis, systemic treatments, IL17 inhibitors, phase 2 trial, JAK inhibitor, and IL12/23 inhibitors. The search included only articles published in English.J Drugs Dermatol. 2022;21(8):826-831. doi:10.36849/JDD.6443.

Original languageEnglish
Pages (from-to)826-831
Number of pages6
JournalJournal of Drugs in Dermatology
Issue number8
StatePublished - 1 Aug 2022


Dive into the research topics of 'New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis'. Together they form a unique fingerprint.

Cite this